NCT03213977 2024-03-27
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University
Phase 3 Unknown
Clinical Trials
139 trialsNCT06033820 2024-03-13
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Phase 2 Unknown
NCT06290817 2024-03-04
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT04870853 2023-11-14
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
M.D. Anderson Cancer Center
Unknown
NCT03121456 2023-11-13
LYMPHODTECT
Centre Antoine Lacassagne
Phase NA Unknown
NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05673447 2023-08-28
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
Phase EARLY_PHASE1 Unknown
NCT05871684 2023-08-01
A Combination Study of CAR-T Therapy in r/r B-NHL
Ruijin Hospital
Phase 2 Unknown
NCT05887726 2023-07-27
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05020392 2023-07-25
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Unknown
NCT05940051 2023-07-11
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05940064 2023-07-11
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT05907447 2023-06-18
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Ruijin Hospital
Unknown
NCT05883709 2023-06-01
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
Unknown
NCT05018520 2023-05-31
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Ruijin Hospital
Phase 3 Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT05863845 2023-05-18
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Phase NA Unknown
NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT05823701 2023-04-21
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05786989 2023-03-28
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma
Chongqing University Cancer Hospital
Phase 4 Unknown
NCT05784987 2023-03-27
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05777369 2023-03-21
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05728632 2023-02-23
CONTROL
Humanitas Hospital, Italy
Phase 3 Unknown
NCT03797170 2023-02-08
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
University of Bologna
Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT04381741 2023-02-06
CICPD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02752815 2022-12-05
Reduced Chemotherapy in Low Risk DLBCL
Ruijin Hospital
Phase 4 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05532761 2022-09-08
QUALITOP CAR-T
Hospices Civils de Lyon
Unknown
NCT05189782 2022-08-31
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT01357733 2022-08-05
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients
The Catholic University of Korea
Phase NA Unknown
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT05444322 2022-07-11
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05428670 2022-06-23
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT03646422 2022-03-31
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia Española de Dermatología
Unknown
NCT04112238 2022-03-22
CNSctDNA
Herlev Hospital
Unknown
NCT05290337 2022-03-22
ZR-CHOP in DLBCL With Specific Gene Abnormality
Fudan University
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05269914 2022-03-08
Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL
The Affiliated Hospital of Qingdao University
Phase NA Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT05208853 2022-01-26
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT03629873 2022-01-03
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown